Combining the receptor tyrosine kinase inhibitor AEE788 and the mammalian target of rapamycin (mTOR) inhibitor RAD001 strongly inhibits adhesion and growth of renal cell carcinoma cells

Combining the receptor tyrosine kinase inhibitor AEE788 and the mammalian target of rapamycin (mTOR) inhibitor RAD001 strongly inhibits adhesion and growth of renal cell carcinoma cells

<p>Abstract</p> <p>Background</p> <p>Treatment options for metastatic renal cell carcinoma (RCC) are limited due to resistance to chemo- and radiotherapy. The development of small-molecule multikinase inhibitors has now opened novel treatment options. We evaluated the i...

Full description

Bibliographic Details
Main Authors:	Jonas Dietger, Hudak Lukasz, Mickuckyte Ausra, Jones Jon, Natsheh Iyad, Engler Johanna, Juengel Eva, Blaheta Roman A
Format:	Article
Language:	English
Published:	BMC 2009-05-01
Series:	BMC Cancer
Online Access:	http://www.biomedcentral.com/1471-2407/9/161

Similar Items

Chronic Sulforaphane Administration Inhibits Resistance to the mTOR-Inhibitor Everolimus in Bladder Cancer Cells
by: Saira Justin, et al.
Published: (2020-06-01)

Novel and evolving therapies in the treatment of malignant phaeochromocytoma: experience with the mTOR inhibitor everolimus (RAD001).
by: Druce, MR, et al.
Published: (2009)

Effects of Resveratrol, Lovastatin and the mTOR-Inhibitor RAD-001 on Insulin-Induced Genomic Damage In Vitro
by: Eman Awad, et al.
Published: (2017-12-01)

Genotype-dependent efficacy of a dual PI3K/mTOR inhibitor, NVP-BEZ235, and an mTOR inhibitor, RAD001, in endometrial carcinomas.
by: Keiko Shoji, et al.
Published: (2012-01-01)

Comparing the Effects of the mTOR Inhibitors Azithromycin and Rapamycin on In Vitro Expanded Regulatory T Cells
by: Marcus Bergström, et al.
Published: (2019-12-01)

The Rapamycin Derivative RAD001 (Everolimus) Inhibits Cell Proliferation and Interacts with the Akt-mTOR-p70S6K Pathway in Human Medullary Thyroid Carcinoma Cells
by: Grozinsky-Glasberg, S, et al.
Published: (2009)

The rapamycin-derivative RAD001 (everolimus) inhibits cell viability and interacts with the Akt-mTOR-p70S6K pathway in human medullary thyroid carcinoma cells.
by: Grozinsky-Glasberg, S, et al.
Published: (2010)

Synergistic antiproliferative effects of an mTOR inhibitor (rad001) plus gemcitabine on cholangiocarcinoma by decreasing choline kinase activity
by: Gigin Lin, et al.
Published: (2018-08-01)

Advances in the mTOR signaling pathway and its inhibitor rapamycin in epilepsy
by: Wei Zhao, et al.
Published: (2023-06-01)

Octreotide and the mTOR inhibitor RAD001 (everolimus) block proliferation and interact with the Akt-mTOR-p70S6K pathway in a neuro-endocrine tumour cell Line.
by: Grozinsky-Glasberg, S, et al.
Published: (2008)

Resistance to the mTOR Inhibitor Temsirolimus Alters Adhesion and Migration Behavior of Renal Cell Carcinoma Cells through an Integrin α5– and Integrin β3–Dependent Mechanism
by: Eva Juengel, et al.
Published: (2014-04-01)

Longitudinal imaging studies of tumor microenvironment in mice treated with the mTOR inhibitor rapamycin.
by: Keita Saito, et al.
Published: (2012-01-01)

The mTOR inhibitor rapamycin synergizes with a fatty acid synthase inhibitor to induce cytotoxicity in ER/HER2-positive breast cancer cells.
by: Chen Yan, et al.
Published: (2014-01-01)

Tumor-Endothelium Cross Talk Blocks Recruitment of Neutrophils to Endothelial Cells: A Novel Mechanism of Endothelial Cell Anergy
by: Roman A. Blaheta, et al.
Published: (2009-10-01)

Triggering of Eryptosis, the Suicidal Erythrocyte Death by Mammalian Target of Rapamycin (mTOR) inhibitor Temsirolimus
by: Abdulla Al Mamun Bhuyan, et al.
Published: (2017-07-01)

The mTOR kinase inhibitor rapamycin decreases iNOS mRNA stability in astrocytes
by: Feinstein Douglas L, et al.
Published: (2011-01-01)

Correction to: The mTOR inhibitor rapamycin down-regulates the expression of the ubiquitin ligase subunit Skp2 in breast cancer cells
by: Ma’anit Shapira, et al.
Published: (2018-07-01)

Mycophenolate mofetil modulates adhesion receptors of the beta1 integrin family on tumor cells: impact on tumor recurrence and malignancy
by: Beecken Wolf-Dietrich, et al.
Published: (2005-01-01)

RAD001 enhances the potency of BEZ235 to inhibit mTOR signaling and tumor growth.
by: Beat Nyfeler, et al.
Published: (2012-01-01)

Synergistic inhibition of human melanoma proliferation by combination treatment with B-Raf inhibitor BAY43-9006 and mTOR inhibitor Rapamycin
by: Slingluff Craig L, et al.
Published: (2005-10-01)

The mTOR Inhibitor Rapamycin Counteracts Follicle Activation Induced by Ovarian Cryopreservation in Murine Transplantation Models
by: Jules Bindels, et al.
Published: (2023-08-01)

Synergism between the mTOR inhibitor rapamycin and FAK down-regulation in the treatment of acute lymphoblastic leukemia
by: Pei-Jie Shi, et al.
Published: (2016-02-01)

A prática de assessoria no AEE
by: Grazielle Franciosi da Silva, et al.
Published: (2020-12-01)

Different patterns of Akt and ERK feedback activation in response to rapamycin, active-site mTOR inhibitors and metformin in pancreatic cancer cells.
by: Heloisa P Soares, et al.
Published: (2013-01-01)

Mechanisms behind Temsirolimus Resistance Causing Reactivated Growth and Invasive Behavior of Bladder Cancer Cells In Vitro
by: Eva Juengel, et al.
Published: (2019-06-01)

Efficacy and safety of mTOR inhibitors (rapamycin and its analogues) for tuberous sclerosis complex: a meta-analysis
by: Min Li, et al.
Published: (2019-02-01)

The mTOR inhibitor Rapamycin protects from premature cellular senescence early after experimental kidney transplantation
by: Uwe Hoff, et al.
Published: (2022-01-01)

The mTOR inhibitor Rapamycin protects from premature cellular senescence early after experimental kidney transplantation.
by: Uwe Hoff, et al.
Published: (2022-01-01)

A New Hypothesis Describing the Pathogenesis of Oral Mucosal Injury Associated with the Mammalian Target of Rapamycin (mTOR) Inhibitors
by: Stephen T. Sonis, et al.
Published: (2023-12-01)

Rapamycin Loaded Solid Lipid Nanoparticles as a New Tool to Deliver mTOR Inhibitors: Formulation and in Vitro Characterization
by: Alice Polchi, et al.
Published: (2016-05-01)

Active-site inhibitors of mTOR target rapamycin-resistant outputs of mTORC1 and mTORC2.
by: Morris E Feldman, et al.
Published: (2009-02-01)

Mechanistic Target of Rapamycin Inhibitors in Renal Cell Carcinoma: Potential, Limitations, and Perspectives
by: Seraina Faes, et al.
Published: (2021-03-01)

Resistance after chronic application of the HDAC-inhibitor valproic acid is associated with elevated Akt activation in renal cell carcinoma in vivo.
by: Eva Juengel, et al.
Published: (2013-01-01)

Regulation of gene expression in hepatic cells by the mammalian Target of Rapamycin (mTOR).
by: Rosa H Jimenez, et al.
Published: (2010-02-01)

Ex pression of Concern: Different Patterns of Akt and ERK Feedback Activation in Response to Rapamycin, Active-Site mTOR Inhibitors and Metformin in Pancreatic Cancer Cells.
by: PLOS ONE Editors
Published: (2023-01-01)

Ex pression of Concern: Different Patterns of Akt and ERK Feedback Activation in Response to Rapamycin, Active-Site mTOR Inhibitors and Metformin in Pancreatic Cancer Cells
Published: (2023-01-01)

Atendimento Educacional Especializado (AEE) e Educação Especial
by: Rosangela Costa Soares Cabral, et al.
Published: (2020-06-01)

New RAD51 Inhibitors to Target Homologous Recombination in Human Cells
by: Irina S. Shkundina, et al.
Published: (2021-06-01)

Influence of the HDAC Inhibitor Valproic Acid on the Growth and Proliferation of Temsirolimus-Resistant Prostate Cancer Cells In Vitro
by: Jasmina Makarević, et al.
Published: (2019-04-01)

Therapeutic control of leishmaniasis by inhibitors of the mammalian target of rapamycin.
by: Fatemeh Khadir, et al.
Published: (2018-08-01)